282 related articles for article (PubMed ID: 37537933)
1. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
Ma C; Li X; Li W; Li Y; Shui F; Zhu P
Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
4. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
[TBL] [Abstract][Full Text] [Related]
5. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis.
Shiau CH; Tsau LY; Kao CC; Peng YC; Bai CH; Wu JC; Hou WH
Int Urol Nephrol; 2024 Apr; 56(4):1359-1381. PubMed ID: 37752340
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
[TBL] [Abstract][Full Text] [Related]
11. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
Zhou Y; Wang FR; Wen FF; Li C; Ye TT
Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.
Afsar B; Afsar RE
Pharmacol Rep; 2023 Feb; 75(1):44-68. PubMed ID: 36534320
[TBL] [Abstract][Full Text] [Related]
13. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
15. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cao H; Rao X; Jia J; Yan T; Li D
Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K; Toyoda M; Hatori N; Saito N; Kanaoka T; Sakai H; Furuki T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
Diabetes Technol Ther; 2021 Feb; 23(2):110-119. PubMed ID: 32721227
[No Abstract] [Full Text] [Related]
18. SGLT2 Inhibitors in the Management of Chronic Kidney Disease: An Expert Consensus.
Jha V; Almeida A; Choudhury AR; Dutta AR; Khullar D; Gokulnath ; Anandh U; Khanna U; Kher V
J Assoc Physicians India; 2022 Oct; 70(10):11-12. PubMed ID: 37355870
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
